• Cellyan Biotechnology filed a Form 12b-25 to delay its annual Form 20-F for the year ended March 31, 2026.
• Delay tied to unanticipated holdups in completing financial statements; filing expected within 15 calendar days of the due date.
• Net loss expected at about $1.09 million versus about $0.03 million a year earlier.
• Revenue expected to fall 39% to $7.56 million; gross profit projected down 43% to $1.39 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellyan Biotechnology Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-084011), on July 31, 2026, and is solely responsible for the information contained therein.